

- B'
124. (New) A crystalline lamotrigine form E.
  125. (New) A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern having peaks at about 9.5, 11.5, 13.8, 22.2 and  $26.7 \pm 0.2$  degrees two-theta.
  126. (New) The crystalline lamotrigine according to claim 125, further characterized by an X-ray powder diffraction pattern having other typical peaks at about 13.0, 14.3, 14.9, 15.7, 17.9, 19.4, 20.9, 24.5, 25.6, 27.3 and  $32.2 \pm 0.2$  degrees two-theta.
  127. (New) A crystalline lamotrigine form E1 characterized by an X-ray powder diffraction pattern as in Fig. 4.
  128. (New) The crystalline lamotrigine form E according to claim 124, wherein the crystalline lamotrigine form E is a 2/3 methanolate.
  129. (New) A crystalline lamotrigine form E1.
  130. (New) A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern having peaks at about 9.6, 13.8, 15.8, 23.1 and  $26.7 \pm 0.2$  degrees two-theta.
  131. (New) The crystalline lamotrigine according to claim 130, further characterized by an X-ray powder diffraction pattern having other typical peaks at about 11.6, 13.0, 14.4, 15.2, 16.2, 17.8, 18.9, 20.1, 21.8, 24.6, 25.6, 26.3, 27.3, 27.7, 28.8, 30.0, 30.7, 31.9, 32.3, 32.7, 34.3 and  $35.9 \pm 0.2$  degrees two-theta.
  132. (New) A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern as in Fig. 5.
  133. The crystalline lamotrigine form E1 according to claim 129, wherein the crystalline lamotrigine form E1 is a 2/3 ethanolate.
  134. A crystalline lamotrigine form H.
  135. A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern having peaks at about 9.6, 10.5, 21.8, 22.2 and  $27.5 \pm 0.2$  degrees two-theta.
  136. The crystalline lamotrigine according to claim 135, further characterized by an X-ray powder diffraction pattern having other peaks at about 12.2, 13.5, 14.7, 15.1, 16.5, 16.7, 17.0, 18.5, 19.5, 20.5, 24.0, 24.6, 25.7, 26.3, 28.4, 28.9, 29.4, 30.5, 31.1, 31.8, 33.3 and  $35.1 \pm 0.2$  degrees two-theta.
  137. A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern as in Fig. 7.
  138. The crystalline lamotrigine form H according to claim 134, wherein the crystalline lamotrigine form H is a monosolvate of ethanol.
  139. A crystalline lamotrigine form J.
  140. A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern having peaks at about 9.5, 10.0, 20.2 and  $26.6 \pm 0.2$  degrees two-theta.
  141. The crystalline lamotrigine according to claim 140, further characterized by an X-ray powder diffraction pattern having other peaks at about 11.6, 12.4, 13.7, 14.8, 15.9,

16.3, 16.6, 17.3, 18.5, 21.0, 21.3, 24.2, 24.4, 24.7, 25.0, 25.5, 26.4, 26.7, 27.8, 29.2, 30.4 and  $35.1 \pm 0.2$  degrees two-theta.

- B'
142. A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern as in Fig. 8.
143. The crystalline lamotrigine form J according to claim 139, wherein the crystalline lamotrigine form J is a monosolvate of isopropanol.
144. A crystalline lamotrigine form O.
145. A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern having peaks at about 9.5, 13.7, 23.0, 26.7, and  $28.7 \pm 0.2$  degrees two-theta.
146. The crystalline lamotrigine according to claim 145, further characterized by an X-ray powder diffraction pattern having other typical peaks at about 8.5, 11.4, 14.2, 15.7, 18.0, 18.9, 24.2, 25.6, 25.9, 27.7, 30.0, 30.7, 32.6, 34.3, and  $34.8 \pm 0.2$  degrees two-theta.
147. A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern as in Fig. 13.
148. The crystalline lamotrigine form O according to claim 144, wherein the crystalline lamotrigine form O is a 2/3 methanolate.
149. A crystalline lamotrigine form Q.
150. A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern having peaks at about 12.4, 13.8, 14.1, 16.6, 17.4, 17.9, 20.0, 21.0, 23.6, 28.8 and  $30.9 \pm 0.2$  degrees 2-theta.
151. The crystalline lamotrigine according to claim 150, further characterized by an X-ray powder diffraction pattern having other typical peaks at about 9.4, 10.0, 26.7, 27.8, and  $28.4 \pm 0.2$  degrees two-theta.
152. A crystalline lamotrigine, characterized by an X-ray powder diffraction pattern as in Fig. 15.
153. The crystalline lamotrigine form Q according to claim 149, wherein the crystalline lamotrigine form Q is a monosolvate of monoisopropanol.

#### REMARKS

This Supplement Amendment is submitted further to the Amendment filed April 17, 2003 (attached herewith). In this Supplemental Amendment, new claims 134-153 are introduced. There is no new matter because these new claims are the same as the deleted claims. Specifically, new claims 134-133 correspond to the deleted claims 17-25; new claims 134-143 correspond to the deleted claims 32-41; new claims 144-148 correspond to the deleted claims 62-66; and new claims 149-153 correspond to the deleted claims 72-76. In the